The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.
Previous studies have demonstrated that the TaqIA polymorphism of the D2 dopamine receptor gene (DRD2) is associated with response to dopaminergic and antidopaminergic treatment in Parkinson's disease (PD) and schizophrenia, respectively. We tested whether the TaqIA genotype in PD is responsible for demand of dopaminergic medication, measured in total dopaminergic load per year of disease, in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Regression analysis yielded no significant differences between the TaqIA genotypes. We conclude that the DRD2 TaqIA polymorphism alone has no pivotal role for interindividual variability of dopaminergic requirement in PD. We propose a practicable system of measuring dopaminergic treatment for future pharmacogenetic studies in PD.
Paus
Sebastian
S
Department of Neurology, University of Bonn, Bonn, Germany. spaus@uni-bonn.de
Grünewald
Anne
A
Klein
Christine
C
Knapp
Michael
M
Zimprich
Alexander
A
Janetzky
Bernd
B
Möller
Jens C
JC
Klockgether
Thomas
T
Wüllner
Ullrich
U
D000368:Aged; D018491:Dopamine Agonists / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D016896:Treatment Outcome
D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2; D007980:Levodopa